Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Operating Income: 2016-2025

Historic Operating Income for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $29.4 million.

  • Tg Therapeutics' Operating Income rose 136.17% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.8 million, marking a year-over-year increase of 20452.28%. This contributed to the annual value of $41.9 million for FY2024, which is 103.21% up from last year.
  • Tg Therapeutics' Operating Income amounted to $29.4 million in Q3 2025, which was down 15.72% from $34.8 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Operating Income peaked at $114.8 million during Q3 2023, and registered a low of -$92.9 million during Q4 2021.
  • For the 3-year period, Tg Therapeutics' Operating Income averaged around $12.3 million, with its median value being $8.8 million (2024).
  • Its Operating Income has fluctuated over the past 5 years, first surged by 428.30% in 2023, then plummeted by 89.17% in 2024.
  • Tg Therapeutics' Operating Income (Quarterly) stood at -$92.9 million in 2021, then grew by 16.58% to -$77.5 million in 2022, then soared by 83.90% to -$12.5 million in 2023, then surged by 339.88% to $29.9 million in 2024, then skyrocketed by 136.17% to $29.4 million in 2025.
  • Its Operating Income was $29.4 million in Q3 2025, compared to $34.8 million in Q2 2025 and $8.6 million in Q1 2025.